glp 1 drugs for weight loss oral Comparing Ozempic, Wegovy and Other GLP-1 No injections GLP-1 Oral Solution – Affordable

doi: 10.1677/jme.0.0100259

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

If prokinetics are required, a short course of domperidone or metoclopramide can be given, but prescribers must bear in mind the contra-indications of their use and that they are recommended for short-term use only (5 days only in the case of metoclopramide, www.bnf.nice.org.uk)

increased risk of kidney, pancreas and gastrointestinal problems Getty Images Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity

Acknowledgments The authors acknowledge the support of the Student Scientific Association at the Department of Diabetology, Warsaw Medical University, Poland

Therapeutic Scope and the Translational Mismatch Problem Clinically, GLP-1RAs are established therapies for obesity and type 2 diabetes (T2D), with expanding indications and ongoing investigation across multiple organ systems